MilliporeSigma has announced that the Life Science business of Merck KGaA has signed a definitive agreement to acquire the chromatography business of JSR Life Sciences.
The acquisition will expand the company’s downstream processing portfolio with advanced Protein A chromatography capabilities.
This will support more efficient and scalable production of biopharmaceutical therapies, including monoclonal antibodies.
The transaction is expected to close by the end of the second quarter of 2026.
“This acquisition will strengthen our position in the bioprocessing market and underscores our commitment to long-term investment in monoclonal antibody production technologies”, said Sebastián Arana, Head of Process Solutions, Life Science business of Merck KGaA.
“By combining JSR’s Protein A expertise with our portfolio, we can further enable customers to advance the speed, efficiency and reliability of antibody therapy production.”
Protein A chromatography plays a critical role in the purification of monoclonal antibodies and therapeutic proteins, which are used for treating cancers, autoimmune diseases and infectious conditions.
This specialised purification process is key to achieving high purity and enhanced drug safety, while also improving manufacturing speed and reliability.
Ultimately, that means helping patients gain faster access to critical therapies.
Based in Belgium, the chromatography business of JSR Life Sciences has more than 50 employees and supplies chromatography solutions to pharmaceutical and biotech manufacturers worldwide.
The company is known for its high-performing Amsphere A3 and Amsphere A+ Protein A resins, which offer superior purification performance and process robustness for a wide range of monoclonal antibodies.
“This acquisition positions our innovative Amsphere Protein A technologies for even greater global impact under Merck's renowned platform."
"This will enable more customers worldwide to accelerate therapies to market with enhanced speed and confidence”, said Tim Lowery, President of JSR Life Sciences.
MilliporeSigma offers a comprehensive portfolio of downstream solutions, including industry-leading filtration technologies, chromatography resins and chemicals, integrated technologies and validation services.
These capabilities support customers in optimising drug development and manufacturing processes with greater speed, safety and reliability.